![]() |
|
|
Forward to a colleague |
||
Access Full Stories US researchers have developed a way of creating primate embryonic stem cells that avoids the need to use fertilised embryos, potentially leading to more ethical ways of curing degenerative diseases... Read Icahn invests in Genzyme, prompts takeover rumours The man often credited with causing Biogen Idec to be put up for sale, billionaire corporate raider Carl Icahn, has invested in Genzyme and promptly started industry tongues wagging about a takeover... Read Targeted lupus treatment on the horizon Researchers have uncovered some of the underlying causes of lupus, and have even suggested certain targeted therapies to tackle the autoimmune disease... Read Preclinical services news in brief In this week's review of activity within the preclinical research services arena, news has emerged involving GATC Biotech, NextGen Sciences and Genedata... Read Drugs moving into the clinic: 35 The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators... Read |
||||||||||||||||||
All News Headlines for: November | October | September |
||||||||||||||||||
CappAero pipettes - ultimate accuracy and intelligent design The cool transparent handle and dash of vibrant colour on the barrel ensures the ColorLine series will be a welcome addition to any laboratory. The distinctive colour of each pipette permits you to quickly identify the volume range of any pipette at a glance... Click Here | ||||||||||||||||||
|
Related Industry News Extra breathing space for epinephrine MDI ban The US Food and Drug Administration (FDA) has given stakeholders an extra month to get their views in on scrapping epinephrine inhalers containing CFCs... Read AMRI continues growth Albany Molecular Research Inc (AMRI) recently turned in Q3 results, posting figures buoyed by continued demand for its pharmaceutical development services... Read PRA's profits will soon be private PRA International continues to see its profits ebb away but will soon face less financial scrutiny as it nears a handover of ownership into private hands. ... Read BioCryst clinical trials debacle highlights protocol perils BioCryst's recent clinical trials debacle highlights the importance of the robust and realistic design of, and careful adherence to, a drug trial protocol... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||